Triple-Targeted Therapy Achieves Durable Pancreatic Tumor Regression Preclinically

Researchers at the Spanish National Cancer Research Center report a three-drug combination that induced complete and lasting regression of pancreatic tumors in preclinical models. This novel approach simultaneously targets RAF1, EGFR, and STAT3 signaling, crucial nodes in aggressive pancreatic ductal adenocarcinoma (PDAC). The findings, reported by Drug Target Review, suggest a path to overcoming significant therapeutic resistance in this deadly cancer.